～Speaker～

Mr. Frank Chung

Associate Marketing Director, GeneReach Biotechnology Corp.

Speaker's Biography

Frank Chung was graduated from National Cheng-Kung University in Taiwan. As a molecular biologist in GeneReach R&D department, Frank is dedicated to developing an innovative platform to integrate nucleic acid extraction and PCR technology, enabling Sample-to-Result PCR testing to be available in 85 minutes. As an Associate Director in GeneReach Marketing Department, Frank devoted himself to promoting POCKIT Central Nucleic Acid for decentralization SARS-CoV-2 testing, making PCR testing available in the medical center and the regional hospital and resource-limited area. Frank believed the idea of decentralization of SARS-CoV-2 testing will be a game-changer on the prevention and control of SARS-CoV-2 transmission now and in the future.

Topic

Decentralization of SARS-CoV-2 testing

Abstract

SARS-CoV-2 has been responsible for more than 196 million cases, with more than 4 million death cases reported worldwide. At the beginning of the SARS-CoV-2 outbreak, the PCR testing capacity was allocated only in the medical center. The capacity increased slowly and was not affordable to provide the diagnosis in time, especially at the peak of pandemics. To increase the capacity and efficiency of SARS-CoV-2 PCR testing, a diagnostic network including the medical center and the regional hospital was established with a PCR system in the minimal training requirement. The concept of decentralized SARS-CoV-2 PCR testing benefits the application of fast on-site border control, quarantine, which reduce the time for diagnosis and the risk of sample transportation.

With the evolution of the SARS-CoV-2 virus, we can expect the demands of SARS-CoV-2 testing will not decrease shortly, and decentralized SARS-CoV-2 testing can help us establish the power of the diagnostic network, mitigate the transmission and control the outbreak.

Slide and Additional Information

Link: https://reurl.cc/4aMgpK